Celularity (NASDAQ:CELU) Stock Price Down 3.4% – Here’s What Happened

Shares of Celularity, Inc. (NASDAQ:CELU) fell 3.4% during trading on Wednesday . The company traded as low as $0.6281 and last traded at $0.6762. Approximately 392,390 shares were traded during trading, an increase of 167% from the average session volume of 146,970 shares. The stock had previously closed at $0.6998.

Celularity Trading Down 6.8%

The stock has a market cap of $17.95 million, a price-to-earnings ratio of -0.19 and a beta of 0.48. The firm’s 50-day moving average is $0.91 and its two-hundred day moving average is $1.16.

Celularity (NASDAQ:CELU) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.85) earnings per share (EPS) for the quarter. The company had revenue of $4.10 million during the quarter.

Institutional Trading of Celularity

A number of institutional investors have recently made changes to their positions in CELU. Geode Capital Management LLC boosted its stake in Celularity by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock worth $178,000 after purchasing an additional 20,876 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Celularity by 35.3% in the third quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock valued at $1,401,000 after buying an additional 176,518 shares during the last quarter. Bank of America Corp DE raised its position in shares of Celularity by 1,538.1% in the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after buying an additional 35,023 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Celularity in the fourth quarter worth about $33,000. Finally, Jane Street Group LLC purchased a new position in shares of Celularity in the fourth quarter worth about $46,000. 19.02% of the stock is owned by institutional investors and hedge funds.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.